Seeking a Population That Derives a Significant Benefit From Prasugrel

Harlan M. Krumholz, MD, SM


Journal Watch 

In This Article


In this trial, greater platelet inhibition with prasugrel than with clopidogrel did not translate into a discernible benefit in patients with acute coronary syndromes who did not undergo revascularization. The lower-cost agent was as good as the higher-cost one.